Published in J Neurosci on September 10, 2003
Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology (2010) 2.31
Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. Brain (2011) 1.55
Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol Disord Drug Targets (2009) 1.30
Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology (2011) 1.21
Advances in non-dopaminergic treatments for Parkinson's disease. Front Neurosci (2014) 0.93
Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity. PLoS One (2010) 0.93
Potent mGluR5 antagonists: pyridyl and thiazolyl-ethynyl-3,5-disubstituted-phenyl series. Bioorg Med Chem Lett (2011) 0.91
Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates. Neuroimage (2008) 0.90
Metabotropic glutamate receptor 4 in the basal ganglia of parkinsonian monkeys: ultrastructural localization and electrophysiological effects of activation in the striatopallidal complex. Neuropharmacology (2012) 0.86
Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats. Neuroscience (2009) 0.85
Therapeutic potential of metabotropic glutamate receptor modulators. Curr Neuropharmacol (2012) 0.85
Adenosine A2A receptor in the monkey basal ganglia: ultrastructural localization and colocalization with the metabotropic glutamate receptor 5 in the striatum. J Comp Neurol (2012) 0.84
Negative versus positive allosteric modulation of metabotropic glutamate receptors (mGluR5): indices for potential pro-cognitive drug properties based on EEG network oscillations and sleep-wake organization in rats. Psychopharmacology (Berl) (2014) 0.83
Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease. Psychopharmacology (Berl) (2005) 0.81
Activation of presynaptic kainate receptors suppresses GABAergic synaptic transmission in the rat globus pallidus. Neuroscience (2007) 0.78
Benzimidazoles as Potent and Orally Active mGlu5 Receptor Antagonists with an Improved PK Profile. ACS Med Chem Lett (2010) 0.77
Mitochondrial toxins in Basal Ganglia disorders: from animal models to therapeutic strategies. Curr Neuropharmacol (2006) 0.75
Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats. Psychopharmacology (Berl) (2009) 0.75
The subthalamic nucleus exerts opposite control on cocaine and 'natural' rewards. Nat Neurosci (2005) 1.21
Enhanced food-related motivation after bilateral lesions of the subthalamic nucleus. J Neurosci (2002) 1.15
Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease. J Neurosci (2007) 1.15
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. J Pharmacol Exp Ther (2011) 1.14
Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J (2009) 1.12
Portable microstimulator for chronic deep brain stimulation in freely moving rats. J Neurosci Methods (2012) 1.09
Excitotoxic lesions of the prelimbic-infralimbic areas of the rodent prefrontal cortex disrupt motor preparatory processes. Eur J Neurosci (2003) 1.02
Synthesis and biological evaluation of 1-amino-2-phosphonomethylcyclopropanecarboxylic acids, new group III metabotropic glutamate receptor agonists. J Med Chem (2007) 1.00
Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci (2002) 0.99
Deep brain stimulation in neurological diseases and experimental models: from molecule to complex behavior. Prog Neurobiol (2009) 0.97
A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential. FASEB J (2012) 0.96
Spatial deficits in a mouse model of Parkinson disease. Psychopharmacology (Berl) (2007) 0.95
Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology (2004) 0.94
Intralaminar thalamic nuclei lesions: widespread impact on dopamine denervation-mediated cellular defects in the rat basal ganglia. J Neuropathol Exp Neurol (2004) 0.93
High frequency stimulation of the subthalamic nucleus has beneficial antiparkinsonian effects on motor functions in rats, but less efficiency in a choice reaction time task. Eur J Neurosci (2003) 0.93
Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission. Eur J Neurosci (2006) 0.92
High-frequency stimulation of the subthalamic nucleus potentiates L-DOPA-induced neurochemical changes in the striatum in a rat model of Parkinson's disease. J Neurosci (2007) 0.86
Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats. Neuropharmacology (2008) 0.85
Dysfunction of the cortico-basal ganglia-cortical loop in a rat model of early parkinsonism is reversed by metabotropic glutamate receptor 5 antagonism. Eur J Neurosci (2005) 0.85
Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease. Neuropsychopharmacology (2008) 0.83
Contributions of dorsal striatal subregions to spatial alternation behavior. Learn Mem (2011) 0.82
Rationale for targeting the thalamic centre-median parafascicular complex in the surgical treatment of Parkinson's disease. Parkinsonism Relat Disord (2009) 0.81
Impact of surgery targeting the caudal intralaminar thalamic nuclei on the pathophysiological functioning of basal ganglia in a rat model of Parkinson's disease. Brain Res Bull (2008) 0.81
Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease. Psychopharmacology (Berl) (2005) 0.81
High frequency stimulation of the subthalamic nucleus impacts adult neurogenesis in a rat model of Parkinson's disease. Neurobiol Dis (2011) 0.81
Effects of intralaminar thalamic nuclei lesion on glutamic acid decarboxylase (GAD65 and GAD67) and cytochrome oxidase subunit I mRNA expression in the basal ganglia of the rat. Eur J Neurosci (2002) 0.80
The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease. J Pharmacol Exp Ther (2006) 0.80
D1 and D2 dopamine receptors contribute to the locomotor response induced by Group II mGluRs activation in the rat nucleus accumbens. Pharmacol Biochem Behav (2002) 0.79
Serotonergic regulation of the GABAergic transmission in the rat basal ganglia. Synapse (2003) 0.78
Selective effects of partial striatal 6-OHDA lesions on information processing in the rat. Eur J Neurosci (2005) 0.78
Forelimb dyskinesia mediated by high-frequency stimulation of the subthalamic nucleus is linked to rapid activation of the NR2B subunit of N-methyl-D-aspartate receptors. Eur J Neurosci (2010) 0.77
Differential effects of prolonged high frequency stimulation and of excitotoxic lesion of the subthalamic nucleus on dopamine denervation-induced cellular defects in the rat striatum and globus pallidus. Eur J Neurosci (2004) 0.77
Progressive brain metabolic changes under deep brain stimulation of subthalamic nucleus in parkinsonian rats. J Neurochem (2015) 0.77
Systemic administration of dizocilpine maleate (MK-801) or L-dopa reverses the increases in GAD65 and GAD67 mRNA expression in the globus pallidus in a rat hemiparkinsonian model. Synapse (2002) 0.77
The added value of rabies virus as a retrograde tracer when combined with dual anterograde tract-tracing. J Neurosci Methods (2010) 0.77
Different functional basal ganglia subcircuits associated with anti-akinetic and dyskinesiogenic effects of antiparkinsonian therapies. Neurobiol Dis (2009) 0.76
Transient hippocampal down-regulation of Kv1.1 subunit mRNA during associative learning in rats. Learn Mem (2005) 0.76
Striatal molecular signature of subchronic subthalamic nucleus high frequency stimulation in parkinsonian rat. PLoS One (2013) 0.76
Kv4 channel blockade reduces motor and neuropsychiatric symptoms in rodent models of Parkinson's disease. Behav Pharmacol (2015) 0.75
Dynamics of executive control and motor deficits in parkinsonian rats. J Neurosci (2011) 0.75
Interaction between the mGlu receptors 5 antagonist, MPEP, and amphetamine on memory and motor functions in mice. Psychopharmacology (Berl) (2012) 0.75